Web-based data management for a phase II clinical trial in ALS

Abstract

The objective was to report on the creation, features and performance of a web-based data management system for a two-stage phase II randomized clinical trial of Co-Enzyme Q10 in ALS. We created a relatively comprehensive web-based data system that provided electronic data entry; patient management utilities; adverse event reporting, safety monitoring, and invoice generation; and standardized coding for medications and adverse events. In stage 1, clinical sites submitted 7207 forms reporting on 105 patients followed for 10 months. Less than 0.7% of submitted forms contained errors. At the time of the delivery of the analysis data set, only four errors remained unresolved. Data were available quickly, with a median time from event to data posting of two days. The data set was locked and the analysis data set produced nine days after the final patient visit. A survey of trial personnel yielded generally positive feedback, with 75% of respondents wishing to use a similar system in the future. Given sufficient resources, a comprehensive web-based data management system can meet the need for clean, available data in clinical trials in ALS and similar diseases, and can contribute significantly to their efficient execution.

A Clinical Data Management System for Diabetes Clinical Trials

“…The user interface of the system was designed using the web-based ASP.NET programming language, which was used in the design of similar systems in other studies [ 32 , 38 ]. Although there are different programming languages that can be used to design data management systems [ 27 , 30 , 41 , 43 ], the .NET framework appears to have comprehensive libraries for developing web-based systems and makes system development easier [ 55 ].…”

Enhancing clinical trials in neurodegenerative disorders

“…Effective implementation of a web-based data management system was demonstrated during the recent clinical trial of coenzyme Q10 in ALS [66]. This allowed for data analysis to begin within days of trial completion, and loss to follow-up rate was minimized as compared with previous ALS trials.…”